Stockholm CF center
Stockholm, Sweden
Location status: Recruiting
NCT Number: NCT06302270
Observational study on women with Cystic Fibrosis treated with CFTR modulators during pregnancy and postpartum and their children. Registration on maternal health parameters and effects of CFTR-modulators in the newborn infant as well as effects of exposure through mother's own milk.
Interested in participating?
Request InfoUp to 50 year
All sexes
Observational
Stockholm, Sweden
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Woman with cystic fibrosis who is pregnant and treated with Kaftrio. Newborn infant to the above mentioned woman
Exclusion criteria
none
Time frame: 6 years
Contact information is provided by the study sponsor or research team.
Terezia Pinzikova
CONTACT
jenny svedenkrans
CONTACT
Region Stockholm
Other Gov
Monitoring of Women and Children Exposed to the Combination of Elexacaftor-tezacaftor-ivacaftor During Bregnancy and Through Mother's Own Milk.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02417740
Cardiovascular Abnormalities, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06654752
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Birmingham, Alabama, United States
View Trial DetailsNCT00001532
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07283770
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Overland Park, Kansas, United States
View Trial Details